Retrospective Cohort Study
Copyright ©The Author(s) 2021.
World J Clin Cases. Jun 26, 2021; 9(18): 4559-4572
Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4559
Figure 1
Full Size Figure Download Figure
Figure 1 Patients’ allocation and survival according to scoring systems in cohort 1 (recommended transarterial chemoembolization patients). NIACE: Number of tumor(s), Infiltrative hepatocellular carcinoma, Alpha-fetoprotein, Child-Pugh class, Eastern Cooperative Oncology Group Performance Status; 6&12: “Six-and-Twelve”; ALBI: Albumin-Bilirubin; NS: Not significant; G: Grade; C: Category; TACE: Transarterial chemoembolization.
  • Citation: Adhoute X, Larrey E, Anty R, Chevallier P, Penaranda G, Tran A, Bronowicki JP, Raoul JL, Castellani P, Perrier H, Bayle O, Monnet O, Pol B, Bourliere M. Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results. World J Clin Cases 2021; 9(18): 4559-4572
  • URL: https://www.wjgnet.com/2307-8960/full/v9/i18/4559.htm
  • DOI: https://dx.doi.org/10.12998/wjcc.v9.i18.4559